BR112022016470A2 - Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamífero - Google Patents
Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamíferoInfo
- Publication number
- BR112022016470A2 BR112022016470A2 BR112022016470A BR112022016470A BR112022016470A2 BR 112022016470 A2 BR112022016470 A2 BR 112022016470A2 BR 112022016470 A BR112022016470 A BR 112022016470A BR 112022016470 A BR112022016470 A BR 112022016470A BR 112022016470 A2 BR112022016470 A2 BR 112022016470A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- methods
- blood glucose
- weight loss
- pharmaceutical dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980093P | 2020-02-21 | 2020-02-21 | |
| US202063122108P | 2020-12-07 | 2020-12-07 | |
| US202163133540P | 2021-01-04 | 2021-01-04 | |
| PCT/US2021/018947 WO2021168386A1 (en) | 2020-02-21 | 2021-02-21 | Glp-1r and gcgr agonists, formulations, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016470A2 true BR112022016470A2 (pt) | 2022-11-22 |
Family
ID=77391258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016470A BR112022016470A2 (pt) | 2020-02-21 | 2021-02-21 | Formulação de dosagem farmacêutica, e, métodos para diminuir a glicemia de um mamífero e para induzir perda de peso em um mamífero |
Country Status (11)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4286400A3 (en) * | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| WO2014081872A1 (en) * | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| US20230317230A1 (en) * | 2019-05-02 | 2023-10-05 | Closed Loop Medicine Ltd. | Method for treating obesity |
| CN117202924A (zh) * | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| US20240148879A1 (en) * | 2021-02-21 | 2024-05-09 | Spitfire Pharma Llc | Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use |
| KR20240118786A (ko) * | 2021-12-01 | 2024-08-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도 |
| KR20250067161A (ko) * | 2022-09-14 | 2025-05-14 | 스핏파이어 파마, 엘엘씨 | Glp-1r 및 gcgr 효능제를 사용하여 지방간 질환을 앓는 피험체에서 체중을 감소시키기 위한 치료 요법 및 방법 |
| WO2024098071A1 (en) * | 2022-11-05 | 2024-05-10 | Spitfire Pharma Llc | Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080280814A1 (en) | 2004-09-17 | 2008-11-13 | Novo Nordisk A/S | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide |
| RU2413530C9 (ru) | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
| EP4286400A3 (en) * | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| WO2014081872A1 (en) * | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| EP2922877B1 (en) * | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| BR112015025464A2 (pt) * | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| CN117582516A (zh) * | 2014-05-28 | 2024-02-23 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| PE20170471A1 (es) | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| JP2017517549A (ja) * | 2014-06-13 | 2017-06-29 | サノフイ | 活性薬剤成分のナノカプセル製剤 |
| JP2018503595A (ja) | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| FI3322437T3 (fi) * | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| BR112018017031A2 (pt) | 2016-02-23 | 2019-01-22 | Sesen Bio Inc | formulações de antagonista de il-6 e usos das mesmas |
| AU2019205905B2 (en) * | 2018-01-03 | 2024-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for treatment of NASH and other disorders |
-
2021
- 2021-02-21 CA CA3168001A patent/CA3168001A1/en active Pending
- 2021-02-21 KR KR1020227032683A patent/KR20220143923A/ko active Pending
- 2021-02-21 WO PCT/US2021/018947 patent/WO2021168386A1/en not_active Ceased
- 2021-02-21 US US17/180,827 patent/US20210290732A1/en active Pending
- 2021-02-21 AU AU2021224246A patent/AU2021224246A1/en active Pending
- 2021-02-21 IL IL295744A patent/IL295744A/en unknown
- 2021-02-21 JP JP2022548518A patent/JP7752619B2/ja active Active
- 2021-02-21 MX MX2022010320A patent/MX2022010320A/es unknown
- 2021-02-21 EP EP21757069.6A patent/EP4106796A4/en active Pending
- 2021-02-21 CN CN202180029769.4A patent/CN115427065A/zh active Pending
- 2021-02-21 BR BR112022016470A patent/BR112022016470A2/pt unknown
-
2025
- 2025-01-22 US US19/034,251 patent/US20250262280A1/en active Pending
- 2025-09-29 JP JP2025162266A patent/JP2026021305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021224246A1 (en) | 2022-09-15 |
| JP2023514992A (ja) | 2023-04-12 |
| CN115427065A (zh) | 2022-12-02 |
| KR20220143923A (ko) | 2022-10-25 |
| EP4106796A1 (en) | 2022-12-28 |
| EP4106796A4 (en) | 2024-04-17 |
| WO2021168386A1 (en) | 2021-08-26 |
| CA3168001A1 (en) | 2021-08-26 |
| JP2026021305A (ja) | 2026-02-10 |
| US20210290732A1 (en) | 2021-09-23 |
| IL295744A (en) | 2022-10-01 |
| US20250262280A1 (en) | 2025-08-21 |
| JP7752619B2 (ja) | 2025-10-10 |
| MX2022010320A (es) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009287A2 (pt) | Agonista do receptor de glp-1 e uso do mesmo | |
| Sicari et al. | The promotion of a constructive macrophage phenotype by solubilized extracellular matrix | |
| MX2022010320A (es) | Agonistas, formulaciones y metodos de uso de glp-1r y gcgr. | |
| Nel et al. | Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel | |
| Hu et al. | Effects of autologous adipose-derived stem cell infusion on type 2 diabetic rats | |
| GT200800037A (es) | Solucion de cloruro de sodio para reconstitucion o dilucion de farmacos | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| Hu et al. | Anti-inflammatory effect of B-type natriuretic peptide postconditioning during myocardial ischemia–reperfusion: involvement of PI3K/Akt signaling pathway | |
| BR112023019201A2 (pt) | Composição farmacêutica aquosa ou composição farmacêutica liofilizada | |
| BR112022013725A2 (pt) | Formulações para agentes terapêuticos proteicos | |
| BR112023017612A2 (pt) | Compostos agonistas do receptor beta do hormônio da tireoide | |
| Biter et al. | Characterization and stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a candidate antigen for a therapeutic vaccine against Chagas disease | |
| Hache et al. | ARA290, a specific agonist of erythropoietin/CD131 heteroreceptor, improves circulating endothelial progenitors’ angiogenic potential and homing ability | |
| BR0311687A (pt) | composições farmacêuticas estabilizadas com base em óleo de rìcino polioxietilado e método para a fabricação das mesmas | |
| BR112015020439A2 (pt) | material de substituição óssea para a cirurgia óssea e dentária e processo de preparação de um material de substituição óssea | |
| JP7255050B2 (ja) | 安定性の増大した哺乳類卵胞刺激ホルモン組成物 | |
| Chang et al. | PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation | |
| Bloch et al. | Hyper-activation of endogenous GLP-1 system to gram-negative sepsis is associated with early innate immune response and modulated by diabetes | |
| Belmiro et al. | Dermatan sulfate reduces monocyte chemoattractant protein 1 and TGF-β production, as well as macrophage recruitment and myofibroblast accumulation in mice with unilateral ureteral obstruction | |
| Yuki et al. | Endothelin-1 stimulates cardiomyocyte injury during mitochondrial dysfunction in culture | |
| JOP20230150A1 (ar) | صيغ ببتيد علاجية | |
| MX2023006696A (es) | Composiciones farmaceuticas que comprenden un agonista cannabinoide. | |
| Raut et al. | An evaluation of the effects of nonselective and cardioselective β-blockers on wound healing in Sprague Dawley rats | |
| Corrêa | Sobre ototyphlonemertes do Brasil | |
| Zhang et al. | Relationship between perioperative cardiovascular risk factors and bone marrow cells from patients undergoing coronary artery bypass grafting surgery |